Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

Chimeric antigen receptor (CAR) T cells are a novel class of anti-cancer therapy in which autologous or allogeneic T cells are engineered to express a CAR targeting a membrane antigen. In Europe, tisagenlecleucel (Kymriah™) is approved for the treatment of refractory/relapsed acute lymphoblastic leu...

Descripción completa

Detalles Bibliográficos
Autores principales: Yakoub-Agha, Ibrahim, Chabannon, Christian, Bader, Peter, Basak, Grzegorz W., Bonig, Halvard, Ciceri, Fabio, Corbacioglu, Selim, Duarte, Rafael F., Einsele, Hermann, Hudecek, Michael, Kersten, Marie José, Köhl, Ulrike, Kuball, Jürgen, Mielke, Stephan, Mohty, Mohamad, Murray, John, Nagler, Arnon, Robinson, Stephen, Saccardi, Riccardo, Sanchez-Guijo, Fermin, Snowden, John A., Srour, Micha, Styczynski, Jan, Urbano-Ispizua, Alvaro, Hayden, Patrick J., Kröger, Nicolaus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2020
Materias:
Guideline Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7012497/
https://www.ncbi.nlm.nih.gov/pubmed/31753925
http://dx.doi.org/10.3324/haematol.2019.229781

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7012497/
https://www.ncbi.nlm.nih.gov/pubmed/31753925
http://dx.doi.org/10.3324/haematol.2019.229781

Ejemplares similares